32 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
of effect in Phase 3 target population Attractive safety profile for chronic treatment Regulatory feedback supportive of single registrational study … chronic treatment in PAH patients Reports of cough diminish as patients get used to DPI Vast majority of patients have reached and maintained 90mg BID
8-K
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
13, 2020, the Company announced topline results from the Company’s Phase 2 trials in patients with moderate-to-severe eosinophilic asthma and chronic … .
The proof-of-concept TITAN trial enrolled 97 patients with chronic rhinosinusitis with and without nasal polyps and assessed treatment with GB001 40 mg vs
8-K
EX-99.2
qaz1zc2
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
o8gg0oxk
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
dh235yxjp07yb 761hny
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
424B5
2r8b0dovm3m
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
nylanj8zm
19 May 20
Prospectus supplement for primary offering
5:08pm
424B5
awyzdb5mh1m snp5zah
18 May 20
Prospectus supplement for primary offering
4:16pm
424B5
hcdff2 b9fmf
18 May 20
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
6yy1ob2o2 dnbf8d0n
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
8-K
EX-99.1
w7q5lpog7 es287y8al
24 Mar 20
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
8:45am
8-K
EX-99.1
mt3u9 v3crapwelx4
12 Nov 19
Gossamer Bio Announces Third Quarter 2019 Financial Results
4:10pm